View Financial HealthNovAccess Global 배당 및 자사주 매입배당 기준 점검 0/6NovAccess Global 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 02NovAccess Global Inc., Annual General Meeting, May 06, 2024NovAccess Global Inc., Annual General Meeting, May 06, 2024, at 12:00 US Eastern Standard Time.공시 • Feb 29NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLCNovAccess Global Inc. announced that it has entered into a securities purchase agreement to issue a promissory note in the principal amount of up to $100,000 on February 27, 2024, The transaction will include participation from new investor, AJB Capital Investments LLC. The notes will have a coupon rate of 12% and the note is due on August 27, 2024.공시 • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2024, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 11NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General. The addition of Dr. Moore brings the NovAccess Global Scientific Advisory Board to 6 members. NovAccess Global intends to leverage the expertise, insight and professional network of Dr. Moore with NIH and other healthcare centers of influence toward accessing government non-dilutive funding, including the White House Cancer Moonshot, amongst other targeted award mechanisms. Dr. Moore will be tapped to assist NovAccess Global to develop collaborations here in the US and overseas. Through Dr. Moore, NovAccess Global will strive to initiate publicly facilitated studies for immune suppressed patients, who are at higher risk for glioblastoma and other cancers. Dr. Moore served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career responsible for global development within the Office of the Secretary, HHS, for Africa and other low- and middle-income regions. Dr. Moore represented HHS in cooperative international efforts in Africa to address continued health and human resources issues. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop. Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.공시 • Jun 02NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare TherapiesNovAccess Global Inc. announced the formation of its Precision Medicine Division to enable more enhanced and accelerated personalised therapeutics and treatment protocols. Using AI, Big Data and Predictive technologies to power its new Precision Medicine Division, NovAccess Global will search through licensed databases to identify patient data (phenotypic, clinical and genomic) for analysis as part of its own and its clients therapeutic drug development and its clients' therapeutic treatment purposes. This service platform also will be marketed to external pharmaceutical and biotechnology companies, private payers, federal and national/international health agencies and healthcare providers. Beyond the glioblastoma/brain tumor segment, NovAccess Global will target cardiology and oncology patient data, with an emphasis on obtaining oncology and cardiology patient data sets from different countries around the world that will include underrepresented patient populations. The Precision Medicine Division has begun developing a platform to allow the analysis of patient data in a manner that will meet the most stringent data privacy requirements. Overall, NovAccess Global expects to have its patient data platform available for commercial use by the end of the first quarter of 2024. NovAccess Global intends to also use AI within its Precision Medicine Division to identify the most optimal antigens use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient. It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.공시 • Dec 30NovAccess Global Inc. announced delayed annual 10-K filingOn 12/29/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 11Novaccess Global Inc. Appoints Peter Weinstein to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Peter Weinstein, PH.D., JD to its Scientific Advisory Board. Dr. Weinstein is a well-regarded intellectual property attorney and healthcare industry consultant who has been serving as legal counsel to NovAccess Global subsidiary StemVax Therapeutics for several years. With the addition of Dr. Weinstein, the NovAccess Global Scientific Advisory Board has five members, with disciplines spanning biotechnology and medical technology IP, healthcare IT, U.S. government agency and grant submissions, oncology drug development, and clinical research. Peter D. Weinstein, Ph.D., J.D counsels in all aspects of intellectual property, transaction and corporate law. He is the founder and Chief Executive Officer of Entralta, an intellectual property management company driven to bring the high quality of work to its clients by focusing on each client's needs. In addition, he is the chief legal counsel to NovAccess Global subsidiary StemVax Therapeutics. Dr. Weinstein received his Juris Doctorate degree at Boston College Law School, and is registered patent attorney licensed to practice law in California and Texas and is admitted to U.S. District Courts located in California and Texas. He also received a Ph.D. in Biology with an emphasis in Immunology from the University of Pennsylvania. Following receipt of his Ph.D., Dr. Weinstein worked as a Research Fellow, first at the National Institutes of Health in Bethesda, Maryland and then at the United States Army Medical Research Institute of Infectious Disease in Frederick, Maryland where he investigated the molecular development of antibody diversity and worked on vaccine development. Prior to forming Entralta, Dr. Weinstein worked for many years as Senior Patent Counsel at Baxter Healthcare Corporation where he was responsible for managing legal and intellectual property matters for Baxter's major hemophilia products like Advate® and major research and development programs in hemophilia that led to the approval by the FDA of Adenovate® and VonVendi®. This work entailed working with multidisciplinary teams in the United States, Europe, and Asia. Earlier, Dr. Weinstein worked in the San Diego Offices of the law firms of Brobeck, Phleger & Harrison, and Fish & Richardson where his practice focused on the management and prosecution of patent portfolios for biotech and high tech companies and patent and general civil litigation. During law school, he worked full-time as a patent agent in the Boston Office of Goodwin Procter. Dr. Weinstein also worked as an Examiner at the United States Patent and Trademark Office followed by a stint as a Senior Scientist at a biotech company where he was responsible for the Animal Health Group developing vaccines and other therapeutics for the treatment of infectious disease in large animals.공시 • Nov 10NovAccess Global Inc., Annual General Meeting, Nov 21, 2022NovAccess Global Inc., Annual General Meeting, Nov 21, 2022, at 11:00 US Eastern Standard Time. Agenda: To consider and review the customary shareholder voting procedures and an investor presentation to be provided by the Company's management; and to discuss any other matters.공시 • Oct 27NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1NovAccess Global Inc. announced the approval of its application with the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. Glioblastoma is a form of aggressive brain cancer that annually impacts approximately 250,000 people globally and is on the rise in many countries, according to NovAccess scientists and published reports. The market data is more alarming, with glioblastoma accounting for approximately 50% of all malignant brain cancers diagnosed in the United States each year, and more than 10,000 Americans dying from this tumor type annually. Less than 5% of people with this cancer live longer than five years after their diagnosis. The global glioblastoma treatment market was estimated to be valued in excess of $2 billion in 2020, with projections for a compounded annual growth rate of more than 8% throughout the remainder of the decade. The FDA's Office of Orphan Products Development grants orphan designation status to investigational drugs and therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug designation provides benefits to drug developers which may include assistance in the drug development process, financial incentives to support clinical development, tax credits for clinical costs, exemptions from certain FDA fees and the potential for seven years of post-approval marketing exclusivity. Sponsors seeking orphan drug designation for a drug must submit a request for designation to the FDA. Orphan drug designation is a separate process from seeking commercial approval or licensing, and the receipt of orphan drug designation status does not change the regulatory requirements or process for obtaining marketing approval from the FDA.공시 • Aug 10NovAccess Global Inc. announced that it expects to receive $0.1 million in fundingNovAccess Global Inc. announced that it issued a convertible promissory note for gross proceeds of $100,000 to Nyla Sakakura-Clark on August 8, 2022. The note bears interest at the rate of 12% per year and is due on August 8, 2023.공시 • May 12NovAccess Global Inc. announced that it has received $0.9 million in funding from AJB Capital Investments LLCOn May 9, 2022, NovAccess Global Inc. closed the transaction.공시 • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Feb 03NovAccess Global Inc. Announces Board ChangesOn January 31, 2022, NovAccess Global Inc. (‘NovAccess’) entered into a preferred stock redemption agreement (‘Agreement’) with TN3, LLC (‘TN3’), Mr. Daniel G. Martin, Irvin Consulting, LLC (‘IC’), and Dr. Dwain Morris-Irvin. Mr. Martin is the company's chairman of the board and owns TN3. Dr. Irvin is the company's chief executive officer and owns IC. Upon completion of the redemption, Mr. Martin will resign from the NovAccess board and be replaced by Dr. Irvin and John Cassarini.공시 • Dec 31NovAccess Global Inc. announced delayed annual 10-K filingOn 12/30/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • May 19NovAccess Global Inc. announced delayed 10-Q filingOn 05/18/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Dec 31NovAccess Global Inc. announced delayed annual 10-K filingOn 12/30/2020, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Oct 29Novaccess Global Inc. Announces Executive ChangesNovAccess Global Inc. announced that L. Michael Yukich joined as fractional chief financial officer, replacing Daniel G. Martin, who had been serving as interim CFO. Mr. Martin remains chairman of the board of directors. Mike Yukich, age 74, has extensive financial and accounting experience and for the past twenty years he has held the position of chief financial officer for both public and private companies. Mr. Yukich currently serves as interim chief financial officer for Innovest Global Inc. Mr. Yukich served as Innovest’s CFO from August 2017 to October 2019 and rejoined the company in September 2020.공시 • Oct 16NovAccess Global Inc. Appoints Dr. Dwain Irvin as CEONovAccess Global Inc. announced the addition of Dr. Dwain Irvin as CEO. Dr. Irvin steps into the role after heading the Biotechnology division for Innovest Global Inc. Dr. Irvin received his PhD from UCLA School of Medicine, MPH, from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.공시 • Aug 18XsunX, Inc. announced delayed 10-Q filingOn 08/17/2020, XsunX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 XSNX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: XSNX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장NovAccess Global 배당 수익률 vs 시장XSNX의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (XSNX)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (XSNX) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 XSNX 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 XSNX 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 XSNX 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: XSNX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 06:19종가2026/05/18 00:00수익2024/09/30연간 수익2024/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스NovAccess Global Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 02NovAccess Global Inc., Annual General Meeting, May 06, 2024NovAccess Global Inc., Annual General Meeting, May 06, 2024, at 12:00 US Eastern Standard Time.
공시 • Feb 29NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLCNovAccess Global Inc. announced that it has entered into a securities purchase agreement to issue a promissory note in the principal amount of up to $100,000 on February 27, 2024, The transaction will include participation from new investor, AJB Capital Investments LLC. The notes will have a coupon rate of 12% and the note is due on August 27, 2024.
공시 • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2024, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 11NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General. The addition of Dr. Moore brings the NovAccess Global Scientific Advisory Board to 6 members. NovAccess Global intends to leverage the expertise, insight and professional network of Dr. Moore with NIH and other healthcare centers of influence toward accessing government non-dilutive funding, including the White House Cancer Moonshot, amongst other targeted award mechanisms. Dr. Moore will be tapped to assist NovAccess Global to develop collaborations here in the US and overseas. Through Dr. Moore, NovAccess Global will strive to initiate publicly facilitated studies for immune suppressed patients, who are at higher risk for glioblastoma and other cancers. Dr. Moore served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career responsible for global development within the Office of the Secretary, HHS, for Africa and other low- and middle-income regions. Dr. Moore represented HHS in cooperative international efforts in Africa to address continued health and human resources issues. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop. Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
공시 • Jun 02NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare TherapiesNovAccess Global Inc. announced the formation of its Precision Medicine Division to enable more enhanced and accelerated personalised therapeutics and treatment protocols. Using AI, Big Data and Predictive technologies to power its new Precision Medicine Division, NovAccess Global will search through licensed databases to identify patient data (phenotypic, clinical and genomic) for analysis as part of its own and its clients therapeutic drug development and its clients' therapeutic treatment purposes. This service platform also will be marketed to external pharmaceutical and biotechnology companies, private payers, federal and national/international health agencies and healthcare providers. Beyond the glioblastoma/brain tumor segment, NovAccess Global will target cardiology and oncology patient data, with an emphasis on obtaining oncology and cardiology patient data sets from different countries around the world that will include underrepresented patient populations. The Precision Medicine Division has begun developing a platform to allow the analysis of patient data in a manner that will meet the most stringent data privacy requirements. Overall, NovAccess Global expects to have its patient data platform available for commercial use by the end of the first quarter of 2024. NovAccess Global intends to also use AI within its Precision Medicine Division to identify the most optimal antigens use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient. It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.
공시 • Dec 30NovAccess Global Inc. announced delayed annual 10-K filingOn 12/29/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 11Novaccess Global Inc. Appoints Peter Weinstein to Scientific Advisory BoardNovAccess Global Inc. announced the appointment of Peter Weinstein, PH.D., JD to its Scientific Advisory Board. Dr. Weinstein is a well-regarded intellectual property attorney and healthcare industry consultant who has been serving as legal counsel to NovAccess Global subsidiary StemVax Therapeutics for several years. With the addition of Dr. Weinstein, the NovAccess Global Scientific Advisory Board has five members, with disciplines spanning biotechnology and medical technology IP, healthcare IT, U.S. government agency and grant submissions, oncology drug development, and clinical research. Peter D. Weinstein, Ph.D., J.D counsels in all aspects of intellectual property, transaction and corporate law. He is the founder and Chief Executive Officer of Entralta, an intellectual property management company driven to bring the high quality of work to its clients by focusing on each client's needs. In addition, he is the chief legal counsel to NovAccess Global subsidiary StemVax Therapeutics. Dr. Weinstein received his Juris Doctorate degree at Boston College Law School, and is registered patent attorney licensed to practice law in California and Texas and is admitted to U.S. District Courts located in California and Texas. He also received a Ph.D. in Biology with an emphasis in Immunology from the University of Pennsylvania. Following receipt of his Ph.D., Dr. Weinstein worked as a Research Fellow, first at the National Institutes of Health in Bethesda, Maryland and then at the United States Army Medical Research Institute of Infectious Disease in Frederick, Maryland where he investigated the molecular development of antibody diversity and worked on vaccine development. Prior to forming Entralta, Dr. Weinstein worked for many years as Senior Patent Counsel at Baxter Healthcare Corporation where he was responsible for managing legal and intellectual property matters for Baxter's major hemophilia products like Advate® and major research and development programs in hemophilia that led to the approval by the FDA of Adenovate® and VonVendi®. This work entailed working with multidisciplinary teams in the United States, Europe, and Asia. Earlier, Dr. Weinstein worked in the San Diego Offices of the law firms of Brobeck, Phleger & Harrison, and Fish & Richardson where his practice focused on the management and prosecution of patent portfolios for biotech and high tech companies and patent and general civil litigation. During law school, he worked full-time as a patent agent in the Boston Office of Goodwin Procter. Dr. Weinstein also worked as an Examiner at the United States Patent and Trademark Office followed by a stint as a Senior Scientist at a biotech company where he was responsible for the Animal Health Group developing vaccines and other therapeutics for the treatment of infectious disease in large animals.
공시 • Nov 10NovAccess Global Inc., Annual General Meeting, Nov 21, 2022NovAccess Global Inc., Annual General Meeting, Nov 21, 2022, at 11:00 US Eastern Standard Time. Agenda: To consider and review the customary shareholder voting procedures and an investor presentation to be provided by the Company's management; and to discuss any other matters.
공시 • Oct 27NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1NovAccess Global Inc. announced the approval of its application with the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. Glioblastoma is a form of aggressive brain cancer that annually impacts approximately 250,000 people globally and is on the rise in many countries, according to NovAccess scientists and published reports. The market data is more alarming, with glioblastoma accounting for approximately 50% of all malignant brain cancers diagnosed in the United States each year, and more than 10,000 Americans dying from this tumor type annually. Less than 5% of people with this cancer live longer than five years after their diagnosis. The global glioblastoma treatment market was estimated to be valued in excess of $2 billion in 2020, with projections for a compounded annual growth rate of more than 8% throughout the remainder of the decade. The FDA's Office of Orphan Products Development grants orphan designation status to investigational drugs and therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug designation provides benefits to drug developers which may include assistance in the drug development process, financial incentives to support clinical development, tax credits for clinical costs, exemptions from certain FDA fees and the potential for seven years of post-approval marketing exclusivity. Sponsors seeking orphan drug designation for a drug must submit a request for designation to the FDA. Orphan drug designation is a separate process from seeking commercial approval or licensing, and the receipt of orphan drug designation status does not change the regulatory requirements or process for obtaining marketing approval from the FDA.
공시 • Aug 10NovAccess Global Inc. announced that it expects to receive $0.1 million in fundingNovAccess Global Inc. announced that it issued a convertible promissory note for gross proceeds of $100,000 to Nyla Sakakura-Clark on August 8, 2022. The note bears interest at the rate of 12% per year and is due on August 8, 2023.
공시 • May 12NovAccess Global Inc. announced that it has received $0.9 million in funding from AJB Capital Investments LLCOn May 9, 2022, NovAccess Global Inc. closed the transaction.
공시 • Feb 16NovAccess Global Inc. announced delayed 10-Q filingOn 02/15/2022, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Feb 03NovAccess Global Inc. Announces Board ChangesOn January 31, 2022, NovAccess Global Inc. (‘NovAccess’) entered into a preferred stock redemption agreement (‘Agreement’) with TN3, LLC (‘TN3’), Mr. Daniel G. Martin, Irvin Consulting, LLC (‘IC’), and Dr. Dwain Morris-Irvin. Mr. Martin is the company's chairman of the board and owns TN3. Dr. Irvin is the company's chief executive officer and owns IC. Upon completion of the redemption, Mr. Martin will resign from the NovAccess board and be replaced by Dr. Irvin and John Cassarini.
공시 • Dec 31NovAccess Global Inc. announced delayed annual 10-K filingOn 12/30/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • May 19NovAccess Global Inc. announced delayed 10-Q filingOn 05/18/2021, NovAccess Global Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Dec 31NovAccess Global Inc. announced delayed annual 10-K filingOn 12/30/2020, NovAccess Global Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Oct 29Novaccess Global Inc. Announces Executive ChangesNovAccess Global Inc. announced that L. Michael Yukich joined as fractional chief financial officer, replacing Daniel G. Martin, who had been serving as interim CFO. Mr. Martin remains chairman of the board of directors. Mike Yukich, age 74, has extensive financial and accounting experience and for the past twenty years he has held the position of chief financial officer for both public and private companies. Mr. Yukich currently serves as interim chief financial officer for Innovest Global Inc. Mr. Yukich served as Innovest’s CFO from August 2017 to October 2019 and rejoined the company in September 2020.
공시 • Oct 16NovAccess Global Inc. Appoints Dr. Dwain Irvin as CEONovAccess Global Inc. announced the addition of Dr. Dwain Irvin as CEO. Dr. Irvin steps into the role after heading the Biotechnology division for Innovest Global Inc. Dr. Irvin received his PhD from UCLA School of Medicine, MPH, from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.
공시 • Aug 18XsunX, Inc. announced delayed 10-Q filingOn 08/17/2020, XsunX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.